Published in final edited form as:

Org Lett. 2018 March 02; 20(5): 1275–1278. doi:10.1021/acs.orglett.7b03977.

Aza-Riley Oxidation of Ugi-Azide and Ugi-3CR Products toward Vicinal Tricarbonyl Amides: Two-Step MCR-Oxidation Methodology Accessing Functionalized α,β -Diketoamides and α,β -Diketotetrazoles

Christopher Foley[†], Arthur Shaw[‡], and Christopher Hulme^{*,†,‡}

[†] Department of Chemistry & Biochemistry, College of Science, University of Arizona, Tucson, Arizona 85721, United States

[‡] Division of Drug Discovery & Development, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States

Abstract

Direct oxidative deamination of glyoxal-derived Ugi-azide and Ugi three-component reaction products readily affords vicinal tricarbonyls (α,β -diketoamides) and α,β -diketotetrazoles with two diversity elements. This significant extension of our previously described multicomponent reaction–oxidative deamination methodology is proposed to proceed through a mechanistically distinct SeO₂-mediated C–N oxidation derived from an active enol of α -amino- β -ketone systems, effectively an aza-Riley oxidation. This methodology accesses diverse VTC systems from prototypical amines, glyoxaldehydes, and isocyanide building blocks in a mere two steps.

Graphical Abstract

Vicinal tricarbonyls (VTCs) are structures of paramount importance as building blocks and often behave as unusual turn-promoting structural elements in macrolide natural products.¹ Particularly noteworthy are vicinal tricarbonyl amides (VTAs, α,β -diketoamides) found in the biologically active natural product macrolides YM47141–2,² FK-506,³ FR-900525,⁴ and rapamycin.^{5,6} Rapamycin and tacrolimus (FK-506) are venerable FDA-approved

*Corresponding Author hulme@pharmacy.arizona.edu.

The authors declare no competing financial interest.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.7b03977.

Experimental procedures, characterization data, and ¹H and ¹³C NMR spectra for new compounds (PDF)

Accession Codes

CCDC 1554390 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

immunosuppressive agents that exist in a hemiketal form (Scheme 1). Additionally, the electrophilic polycarbonyl framework can be seen foundationally embedded in many heterocyclic structures, accessible through nucleophilic additions to the VTC system. Privileged heterocycles⁷ accessible through such additions are exemplified by pyrroles, imidazoles, isoquinolines, quinoxalines, and furans.^{8–11}

Notable examples of VTCs as building blocks in the total synthesis of natural products¹² include cladoniamide F/G,¹³ papaveraldine, polstatin, prodigiosin,¹⁴ and vasicine.¹⁵ Perhaps even more interesting, cyclic VTC ninhydrin (indane-1,2,3-trione) and acyclic VTCs have been used as carbonyl sources in multicomponent reactions (MCRs).^{16–18} Two approaches toward vicinal tricarbonyls predominate: direct or indirect oxidation of β -diketones. The most common is indirect oxidation of β -diketones by Regitz diazo transfer/oxidation with *t*-BuOCl or DMDO.¹⁹ One step direct oxidation is more attractive, of which previous methods involving organoiodine-chemistry have recently been improved upon.^{20,21}

Ultimately, these protocols rely on an oxidative reaction involving a (modified) central C₂ methylene of a β -diketone, typically in the form of β -ketoesters and β -ketoamides (Scheme 2). The former are readily prepared by the Claisen reaction.²² However, diverse sets of β -ketoamides are difficult to prepare, with recent methodology offering some improvement.²³ Unfortunately, in both cases β -diketone syntheses require catalysts or metal reagents and are restricted by a lack of diversity elements.

As such, we rationalized that our previous postcondensation oxidative deamination methodology,²⁴ which employed aldehydes, could be utilized analogously on glyoxal derived α -amino- β -ketoamides **1** and α -amino- β -ketotetrazoles **3**, affording α,β -diketoamides **2** and α,β -diketotetrazoles **4** (Scheme 2).

Fundamentally, the key C₂ center is derived from the terminal aldehydic carbon of the glyoxal, and the C₃ carbonyl is generated as a functionalized secondary amide, derived from the isocyanide diversity reagent. Interestingly, to the best of our knowledge, MCR products have never been rationally utilized as *pro*-VTC β -diketone synthons. As such, this work provides a substantial improvement on current direct oxidation methodology of β -ketoamides as the challenges associated with their syntheses and the restriction in diversity elements are negated due to the wide availability of diverse glyoxals and isocyanides; notably, the latter have high compatibility with MCR methodology.²⁵

A collection of secondary-amide-containing α,β -diketoamide building blocks (**9**, Scheme 3) was produced by direct oxidative deamination of α -amino- β -ketoamide products **8** of the Ugi-3CR¹⁸ derived from the phenylphosphinic acid catalyzed condensation of aniline, **5**, glyoxals **6**, and isocyanides **7**. The oxidative deamination of the corresponding Ugi-3CR products **8a–f** [2 equiv of SeO₂, dioxane/H₂O (9:1), microwave 160 °C, 5 min to 1 h] ultimately afforded products with a variety of aryl groups **9a–c**, a naphthalene **9d**, and 3,4-(methylenedioxy)-benzene **9e**, coupled with examples of aromatic and aliphatic functionality at R₂ in good yield (49–78%). The related formation of oxomalonamide **9f** was also feasible (53%). Attempts to optimize yields by replacement of aniline **5** with piperidine, pyrrolidine, or *o*-aminoacetophenone in the MCR proved detrimental, and that process was not

investigated further. Note that the purified α,β -diketoamides **9a–f** were characterized as a mixture of the tricarbonyl ketone and hydrate (i.e., a *gem*-diol), as is commonly observed with this functional group. To show utility as building blocks to access further diversity,²⁶ pyrazines **11a–c** and quinoxaline **11d** were produced by condensation of ethylenediamines **10** (2 equiv) with the corresponding α,β -diketoamides **9** by heating at 120 °C for 0.5 h in EtOH/AcOH (ratio 9:0.5 v/v) under microwave irradiation (Scheme 4) (61–81% yield).

Satisfied with these results, further study of the oxidative deamination methodology was directed toward unreported α,β -diketotetrazoles. Containing a 1,5-disubstituted tetrazole, these VTC analogues were proposed to be potential *cis*-amide bioisosteres²⁷ of α,β -diketoamides and, thus, potentially valuable electrophilic tetrazole building blocks.²⁸

The Ugi-azide reaction proceeded smoothly with the amine **5**, glyoxal **6**, and isocyanide **7** (stoichiometry 1:1:1) to afford the α -amino- β -ketotetrazole **12** (Scheme 5). Interestingly, initial oxidative deamination attempts on **12** under similar conditions to those employed to generate α,β -diketoamides **9** (60 min, 160 °C, MW) produced none of the desired α,β -diketotetrazole **13**. However, reducing the reaction time from 1 h to 1 min afforded the desired product **13** (20% yield) and its imine congener **14** (40% yield). Attempts to convert the imine **14** to **13** in situ with addition of 3 M aqueous HCl to the reaction mixture failed to garner **13** yet surprisingly afforded 1-(4-bromophenyl)tetrazole **15** (48%, yield) and an unidentifiable side product (Scheme 5).

To circumvent formation of the stable imine **14**, *N*-methylaniline and piperidine were used as 2° amine inputs **16** in the Ugi-azide MCR. Subsequently, optimization of the temperature and reaction time of the oxidative deamination step on the 3° amine **17** (140 or 150 °C, 5 min) afforded a collection of α,β -diketotetrazoles **18a–h** (Scheme 6) with good reaction scope and yields. Products were prepared from a variety of isocyanides and aryl glyoxals **18a–g** (30–74% yield) or ethyl glyoxylate **18h** (78% yield).

Encouragingly, the protocol was amenable to convertible isocyanides, which feasibly will allow access to free tetrazoles upon cleavage of the isocyanide substituent.²⁵ A noteworthy example is the α,β -diketotetrazole **18h**, which may be viewed as the tetrazole isologue of ethyl benzoyl formate and *cis*-amide bioisostere of oxomalonamide. Unfortunately, access to the pyruvaldehyde-derived **18i** proved incompatible with these reaction conditions. No starting material was recovered, and the only identified product was the *N*₁-benzyl tetrazole analogue of **15**.

Mechanistically, we propose the reactivity of these α -amino- β -ketoamide systems with SeO₂ at elevated temperatures follows what could be called an aza-Riley oxidation. In previous work, we described oxidative deamination of α -amino amides mediated by [2,3]-sigmatropic rearrangement of a penultimate *N*-selenamidate.²⁴ Indeed, early studies of SeO₂ mediated α -oxidations of carbonyls,²⁹ alongside a pK_a analysis of the α -hydrogens of these respective systems indicates that α -amino- β -ketoamides and α -amino- β -ketotetrazoles **19** can form enol **20** and then react with SeO₂, generating selenohemiaminal **21** (Scheme 7). Note that 2 equiv of SeO₂ are required as incomplete conversion and isolation of imines are observed when 1 equiv is used.

We believe that this enolization-mediated oxidation pathway does not seem to occur with α -amino amides as previously reported due to their lack of acidic α -hydrogens.

Selenohemiaminal **21** is then unable to undergo the traditional Riley oxidation pathway via a Pummerer-like rearrangement³⁰ to the corresponding ketone due to a lack of available *ipso* hydrogens. Instead, **21** is oxidized to iminium species **22** via elimination of selenediol, which is then hydrolyzed to α,β -diketoamide **23**. In the case of α,β -diketotetrazole congeners of **23** (**18a–18h**), upon prolonged heating we have also observed the benzilic acid rearrangement³¹ with loss of formic acid to form α -ketotetrazoles **24**. The previous observation of 1-(4-bromophenyl)tetrazole **15**, likely originates from a nonspecific addition–elimination pathway due to the stability of the substituted tetrazole nucleus as a leaving group. These are observed as common major side products upon prolonged heating. X-ray crystallography of **18f** (see the Supporting Information) supports our claims regarding the unstable nature of the α,β -diketotetrazole systems under the conditions employed. The O₃–C₈–C₉–O₄ torsion angle is $\sim 90^\circ$ (92.09°), while the bond angles at C₈ and C₉ are close to those typical for sp₂ hybridization.

Hence, the π -system between C₈ and C₉ is broken, leading to an elongated C₈–C₉ bond (1.543 Å). Indeed, the torsion angles, bond lengths, and perpendicularity of both halves of each carbonyl system are nearly identical to that seen in the 1,2-diketone benzil.³² Such 1,2-diketone character might further support our proposed mechanisms of rapid conversion to observed decomposition side-products.

Indeed, in comparison to X-ray structures of other α,β -diketoamides,^{1,21} the α,β -diketotetrazoles do not appear to show exact structural bioisosterism. However, α,β -diketotetrazoles do appear to behave analogously to α,β -diketoamides in carbonyl addition reactions and ultimately produce bioisosteric products, although they are much more reactive than the corresponding α,β -diketoamides in both their synthetic procurement and synthetic utilization.

To demonstrate utility, we employed straightforward 1,2-dicarbonyl chemistry (Scheme 8). Thus, condensation of **18c** with 4,5-dimethylphenylenediamine **25** in methanol/acetic acid promoted by microwave irradiation followed by direct crystallization from the reaction mixture produced 2-tetrazoylquinoxaline **26** (31% yield). However, condensation of **18c** with 1,2-ethylenediamine **27** afforded the 2-tetrazolylpyrazine **28** (37%) and the α -ketoamide **29** (50%), respectively, demonstrating that α,β -diketotetrazoles can function as acylating agents analogous to ethyl benzoyl formate in the synthesis of α -ketoamides. Although not directly competitive with many of the methods to synthesize α -ketoamides,^{24,33} optimization of conditions will allow for the synthesis of other challenging *N*-bifunctional α -ketoamide analogues of **29**.

In summary, we have revealed an appealing and highly concise route to vicinal tricarbonyl amides containing two points of embedded diversity. The method improves upon existing routes in its simplicity while offering the ability to rapidly assemble collections of a fundamental key building block for further diversification. Moreover, we have reported the

first route to unique VTA *pro*-bioisosteric building blocks, α,β -diketotetrazoles, which display interesting geometry and reactivity, worthy of further investigation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We thank The University of Arizona Chemistry & Biochemistry for NIH training grant T32 GM008804.

REFERENCES

- (1). (a)Rubin MB; Gleiter R Chem. Rev 2000, 100, 1121. [PubMed: 11749259] (b)Wasserman HH; Parr J Acc. Chem. Res 2004, 37, 687. [PubMed: 15379584]
- (2). Wasserman HH; Chen JH; Xia M Helv. Chim. Acta 2000, 83, 2607.
- (3). Jones TK; Mills SG; Reamer RA; Askin D; Desmond R; Volante RP; Shinkai IJ Am. Chem. Soc 1989, 111, 1157.
- (4). Hatanaka H; Kino T; Miyata S; Inamura N; Kuroda A; Goto T; Tanaka H; Okuhara MJ Antibiot. 1988, 41, 1592.
- (5). Nicolaou KC; Chakraborty TK; Piscopio AD; Minowa N; Bertinato PJ Am. Chem. Soc 1993, 115, 4419.
- (6). Vezina C; Kudelski A; Sehgal SN J. Antibiot 1975, 28, 721. [PubMed: 1102508]
- (7). Vitaku E; Smith DT; Njardarson JT J. Med. Chem 2014, 57, 10257. [PubMed: 25255204]
- (8). Wasserman HH; Cook JD; Fukuyama JM; Rotello VM Tetrahedron Lett. 1989, 30, 1721.
- (9). Brackeen MF; Stafford JA; Feldman PL; Karanewsky DS Tetrahedron Lett. 1994, 35, 1635.
- (10). Wasserman HH; Amici R; Frechette R; Van Duzer JH Tetrahedron Lett. 1989, 30, 869.
- (11). Hoffman RV; Kim HO; Wilson AL J. Org. Chem 1990, 55, 2820.
- (12). Wasserman HH; Lee G Tetrahedron Lett 1994, 35, 9783.
- (13). Selter L; Zygalski L; Kerste E; Koert U Synthesis 2016, 49, 17.
- (14). Schütte J; Kilgenstein F; Fischer M; Koert U Eur. J. Org. Chem 2014, 2014, 5302.
- (15). Wasserman HH; Kuo GH Tetrahedron Lett. 1991, 32, 7131.
- (16). Sha Q; Arman H; Doyle MP Org. Lett 2015, 17, 3876. [PubMed: 26185966]
- (17). Hulme C; Ayaz M; Martinez-Ariza G; Medda F; Shaw A in Recent Advances in Multicomponent Reaction Chemistry In Small Molecule Medicinal Chemistry: Strategies and Technologies; Czechtizky W, Hamley P, Eds.; Wiley & Sons, Inc.: Hoboken, NJ, 2015; Chapter 6, pp 1–43.
- (18). Pan SC; List B Angew. Chem., Int. Ed 2008, 47, 3622.
- (19). Regitz M; Adolph HGZ Naturforsch., B: J. Chem. Sci 1968, 23, 1269.
- (20). (a)Batchelor MJ; Gillespie RJ; Golec JMC; Hedgecock CJ R. Tetrahedron Lett. 1993, 34, 167. (b)Santos MS; Coelho F RSC Adv. 2012, 2, 3237.
- (21). (a)Cui J; Duan Y-N; Yu J; Zhang C Org. Chem. Front 2016, 3, 1686.(b)Liu Y; Zhang Z; Wan Y; Zhang G; Li Z; Bi J; Ma N; Liu T; Liu QJ Org. Chem 2017, 82, 3901.
- (22). Sprague JM; Beckham LJ; Adkins HJ Am. Chem. Soc 1934, 56, 2665.
- (23). Vandavasi JK; Hsiao CT; Hu WP; Boominathan SSK; Wang JJ Eur. J. Org. Chem 2015, 2015, 3171.
- (24). (a)Foley C; Shaw A; Hulme C Org. Lett 2016, 18, 4904. [PubMed: 27631344] (b)Foley C; Shaw A; Hulme C Org. Lett 2017, 19, 2238. [PubMed: 28409929] (c)Shaw AY; Denning CR; Hulme C Tetrahedron Lett. 2012, 53, 4151. [PubMed: 23180891]
- (25). Giustiniano M; Basso A; Mercalli V; Massarotti A; Novellino E; Tron GC; Zhu J Chem. Soc. Rev 2017, 46, 1295. [PubMed: 27983738]

- (26). Hulme C; Bienayme H; Nixey T; Chenera B; Jones W; Tempest P; Smith AL *Methods Enzymol.* 2003, 369, 469. [PubMed: 14722968]
- (27). Gunawan S; Petit J; Hulme C *ACS Comb. Sci* 2012, 14, 160. [PubMed: 22330239]
- (28). Moderhack D *Heterocycles* 2017, 94, 195.
- (29). Riley HL; Morley JF; Friend NAC *J. Chem. Soc* 1932, 1875.
- (30). Reich HJ; Renga JM; Reich IL *J. Org. Chem* 1974, 39, 2133.
- (31). Askin D; Reamer RA; Jones TK; Volante RP; Shinkai I *Tetrahedron Lett.* 1989, 30, 671.
- (32). Brown CJ; Sadanaga R *Acta Crystallogr.* 1965, 18, 158.
- (33). Shaw AY; Denning CR; Hulme C *Synthesis* 2013, 45, 459.

Scheme 1.

Natural Product Macrolides Embedded with Vicinal Tricarbonyl Amides

Scheme 2.
Routes to Vicinal Tricarbonyls

Scheme 3.

Ugi-3CR of Amines, Glyoxals, and Isonitriles by Oxidative Deamination

^a Aniline used in the initial MCR. ^b Anhydrous dioxane used.

Scheme 4.
Condensations of Vicinal Tricarbonyls

Scheme 5.
Ugi-Azide Reaction of Amines, Glyoxals, and Isonitriles Proceeded by Oxidative Deamination

Scheme 6.

Ugi-Azide Reaction of Amines, Glyoxals, and Isonitriles by Oxidative Deamination

^a5 min, 150 °C, ^b*N*-Methylaniline used in the initial MCR. ^cPiperidine used in the initialMCR. ^d5 min, 140 °C. ^ePercent yield based on recovery of starting material. ^f1 min, 140 °C.

Scheme 7. Proposed Mechanism for Aza-Riley Oxidation of α -Amino β -Ketones

Scheme 8.
Condensations of α,β -Diketotetrazoles